Question follow-through · 18237
Futibatinib
To ask the Secretary of State for Health and Social Care, what funding is available for patients to receive the immunotherapy drug Futibatinib through the NHS; and what criteria his Department uses to determine whether a patient is eligible for any fundin
About this written question
A written question asks a government minister for information in writing. Parliament publishes the question and any answer.
- Answering body
- Department of Health and Social Care
- Tabled
- 5 Dec 2024
- Target answer date
- 11 Dec 2024
- Answer
- 11 Dec 2024 · 6 calendar days after tabling
Elapsed calendar days describe the record timeline, not whether Parliament considers an answer on time.
Votes on this topic
- Terminally Ill Adults (End of Life) Bill: Second Reading · 11 Sept 2026
- Health Bill: Report Stage: Amendment 1 · 8 Sept 2026
- Health Bill: Report Stage: New Clause 143 · 8 Sept 2026
These Commons divisions share a topic label. The question did not necessarily lead to a vote.
Recorded timeline
5 Dec 2024
Question tabled
To ask the Secretary of State for Health and Social Care, what funding is available for patients to receive the immunotherapy drug Futibatinib through the NHS; and what criteria his Department uses to determine whether a patient is eligible for any fundin
11 Dec 2024
Target answer date
Date supplied by the official written-questions record.
11 Dec 2024
Answer published
NHS England funds the use of licensed medicines that have been recommended by the National Institute for Health and Care Excellence (NICE). Futibatinib is licensed by the Medicines and Healthcare products Regulatory Agency and has been recommended by the ...
Official data retrieved 27 Sept 2026.
Later records
Possible follow-up questions
Strong links require the same MP, department and exact heading. Other same-department questions are shown as unreviewed candidates, not as confirmed follow-ups. No debate link is asserted unless a stable source relationship exists.
No later same-department questions indexed.
This is an absence in covered public data, not evidence that no follow-up occurred elsewhere.